455 related articles for article (PubMed ID: 32486345)
1. Matrix Metalloproteinases as Biomarkers of Atherosclerotic Plaque Instability.
Olejarz W; Łacheta D; Kubiak-Tomaszewska G
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486345
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinases in acute coronary syndromes: current perspectives.
Kampoli AM; Tousoulis D; Papageorgiou N; Antoniades C; Androulakis E; Tsiamis E; Latsios G; Stefanadis C
Curr Top Med Chem; 2012; 12(10):1192-205. PubMed ID: 22519449
[TBL] [Abstract][Full Text] [Related]
3. Multidimensional Contribution of Matrix Metalloproteinases to Atherosclerotic Plaque Vulnerability: Multiple Mechanisms of Inhibition to Promote Stability.
Ruddy JM; Ikonomidis JS; Jones JA
J Vasc Res; 2016; 53(1-2):1-16. PubMed ID: 27327039
[TBL] [Abstract][Full Text] [Related]
4. [Matrix metalloproteinases and atherosclerosis].
Fic P; Zakrocka I; Kurzepa J; Stepulak A
Postepy Hig Med Dosw (Online); 2011 Jan; 65():16-27. PubMed ID: 21357991
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinases: influence on smooth muscle cells and atherosclerotic plaque stability.
Johnson JL
Expert Rev Cardiovasc Ther; 2007 Mar; 5(2):265-82. PubMed ID: 17338671
[TBL] [Abstract][Full Text] [Related]
6. Evidence for the Involvement of Matrix-Degrading Metalloproteinases (MMPs) in Atherosclerosis.
Brown BA; Williams H; George SJ
Prog Mol Biol Transl Sci; 2017; 147():197-237. PubMed ID: 28413029
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinases in pro-atherosclerotic arterial remodeling.
Myasoedova VA; Chistiakov DA; Grechko AV; Orekhov AN
J Mol Cell Cardiol; 2018 Oct; 123():159-167. PubMed ID: 30172754
[TBL] [Abstract][Full Text] [Related]
8. Matrix Metalloproteinase 9 as a Predictor of Coronary Atherosclerotic Plaque Instability in Stable Coronary Heart Disease Patients with Elevated Lipoprotein(a) Levels.
Ezhov M; Safarova M; Afanasieva O; Mitroshkin M; Matchin Y; Pokrovsky S
Biomolecules; 2019 Mar; 9(4):. PubMed ID: 30934954
[TBL] [Abstract][Full Text] [Related]
9. The role of matrix metalloproteinases in atherothrombosis.
Ketelhuth DF; Bäck M
Curr Atheroscler Rep; 2011 Apr; 13(2):162-9. PubMed ID: 21271310
[TBL] [Abstract][Full Text] [Related]
10. Gene expression levels of matrix metalloproteinases in human atherosclerotic plaques and evaluation of radiolabeled inhibitors as imaging agents for plaque vulnerability.
Müller A; Krämer SD; Meletta R; Beck K; Selivanova SV; Rancic Z; Kaufmann PA; Vos B; Meding J; Stellfeld T; Heinrich TK; Bauser M; Hütter J; Dinkelborg LM; Schibli R; Ametamey SM
Nucl Med Biol; 2014 Aug; 41(7):562-9. PubMed ID: 24853402
[TBL] [Abstract][Full Text] [Related]
11. Macrophage-mediated proteolytic remodeling of the extracellular matrix in atherosclerosis results in neoepitopes: a potential new class of biochemical markers.
Skjøt-Arkil H; Barascuk N; Register T; Karsdal MA
Assay Drug Dev Technol; 2010 Oct; 8(5):542-52. PubMed ID: 20662734
[TBL] [Abstract][Full Text] [Related]
12. Vascular extracellular matrix in atherosclerosis.
Chistiakov DA; Sobenin IA; Orekhov AN
Cardiol Rev; 2013; 21(6):270-88. PubMed ID: 23422022
[TBL] [Abstract][Full Text] [Related]
13. Association between circulating matrix metalloproteinase levels and coronary plaque regression after acute coronary syndrome--subanalysis of the JAPAN-ACS study.
Ogita M; Miyauchi K; Morimoto T; Daida H; Kimura T; Hiro T; Nakagawa Y; Yamagishi M; Ozaki Y; Matsuzaki M
Atherosclerosis; 2013 Jan; 226(1):275-80. PubMed ID: 23159100
[TBL] [Abstract][Full Text] [Related]
14. Doxycycline stabilizes vulnerable plaque via inhibiting matrix metalloproteinases and attenuating inflammation in rabbits.
Dong M; Zhong L; Chen WQ; Ji XP; Zhang M; Zhao YX; Li L; Yao GH; Zhang PF; Zhang C; Zhang L; Zhang Y
PLoS One; 2012; 7(6):e39695. PubMed ID: 22737253
[TBL] [Abstract][Full Text] [Related]
15. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro.
Aikawa M; Rabkin E; Sugiyama S; Voglic SJ; Fukumoto Y; Furukawa Y; Shiomi M; Schoen FJ; Libby P
Circulation; 2001 Jan; 103(2):276-83. PubMed ID: 11208689
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinases and atherosclerosis.
Watanabe N; Ikeda U
Curr Atheroscler Rep; 2004 Mar; 6(2):112-20. PubMed ID: 15023295
[TBL] [Abstract][Full Text] [Related]
17. Inhibiting extracellular matrix metalloproteinase inducer maybe beneficial for diminishing the atherosclerotic plaque instability.
Xie S; Nie R; Wang J
J Postgrad Med; 2009; 55(4):284-6. PubMed ID: 20083879
[TBL] [Abstract][Full Text] [Related]
18. Circulating and adipose tissue matrix metalloproteinases in cardiometabolic risk environments: pathophysiological aspects.
Berg G; Schreier L; Miksztowicz V
Horm Mol Biol Clin Investig; 2014 Feb; 17(2):79-87. PubMed ID: 25372732
[TBL] [Abstract][Full Text] [Related]
19. The Role of Matrix Metalloproteinase-9 in Atherosclerotic Plaque Instability.
Li T; Li X; Feng Y; Dong G; Wang Y; Yang J
Mediators Inflamm; 2020; 2020():3872367. PubMed ID: 33082709
[TBL] [Abstract][Full Text] [Related]
20. Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition on serum matrix metalloproteinase-13 and tissue inhibitor matrix metalloproteinase-1 levels as a sign of plaque stabilization.
Cevik C; Otahbachi M; Nugent K; Warangkana C; Meyerrose G
J Cardiovasc Med (Hagerstown); 2008 Dec; 9(12):1274-8. PubMed ID: 19001938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
